Day: July 30, 2025

Press Release: Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma

Written by Customer Service on July 30, 2025. Posted in Public Companies.

Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myelomaDesignation granted for IgG1-based GPRC5D monoclonal antibody for the potential treatment of patients with relapsed or refractory multiple myelomaParis, July 30, 2025. The US Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, an IgG1-based Antibody-Dependent Cellular Cytotoxicity-enhanced (ADCC) monoclonal antibody (mAb) targeting G-protein coupled receptor family C group 5 member D (GPRC5D) for the potential treatment of patients with relapsed or refractory multiple myeloma (R/R MM). GPRC5D is highly expressed on plasma cells in MM patients, with low expression in healthy tissues. The FDA grants orphan drug designation to investigational therapies addressing rare medical diseases or conditions...

Melexis Q2 2025 results

Written by Customer Service on July 30, 2025. Posted in Public Companies.

Regulated information Intermediate declaration by the Board of Directors Ieper, Belgium – July 30th, 2025, 07.00 hrs CETDear, Please find herewith the link to our most recent press release: https://www.melexis.com/en/news/2025/financial/melexis-q2-2025-resultsAttachment250730 PR_ENG_Melexis_Q2 2025 final

Solvay second quarter 2025 results

Written by Customer Service on July 30, 2025. Posted in Public Companies.

Press release Regulated information Continued solid EBITDA margin and Free cash flow delivery, despite soft demand environment Brussels, July 30, 2025, 7.00am CEST HighlightsUnderlying net sales in Q2 2025 of €1,102 million were down -3.8% organically compared to Q2 2024 due to the soft market environment, impacted by ongoing tariff and geopolitical tensions. This resulted in a continued reduction of short term demand, particularly visible in certain soda ash and Coatis end-markets. Underlying EBITDA in Q2 2025 decreased year-on-year to €230 million, -12.4% organically compared to Q2 2024 which was the strongest quarter of last year. Q2 2025 was supported by a one-off gain of c. €20 million impacting both revenue and EBITDA resulting from the termination...

Strong sales acceleration of QUVIVIQ drives Idorsia toward profitability – H1 2025 results

Written by Customer Service on July 30, 2025. Posted in Public Companies.

Ad hoc announcement pursuant to Art. 53 LRQUVIVIQ™ (daridorexant): Strong performance and sales acceleration with total net sales of CHF 58 million in H1 2025 and increase of 145% compared to the same period in 2024, largely driven by sales in Europe. NDA approval with Simcere in China. Aprocitentan (TRYVIO/JERAYGO) commercial opportunity significantly improved with REMS removal and very positive real-world experience – engaging in partnership discussions. Net revenue H1 2025 of CHF 131 million – boosted by the CHF 32 million exclusivity fee and CHF 40 million milestone from Simcere recognized in H1 2025. US GAAP operating income H1 2025 of CHF 64 million and non-GAAP operating loss of CHF 15 m. Cash runway extended to the end of 2026 – on track to reach commercial profitability goal in 2026 and overall profitability starting...

JDE Peet’s reports half-year results 2025

Written by Customer Service on July 30, 2025. Posted in Public Companies.

Strong, broad-based performance across top-line, profitability and cash flowFY 25 outlook raised PRESS RELEASEAmsterdam, July 30, 2025 Key items1Organic sales up +22.5%, driven by +21.5% price and +1.0% volume/mix; Reported sales up 19.8%Organic adjusted gross profit up +2.2%; Reported gross profit down -8.7%2Organic adjusted EBIT up +2.0%Free cash flow of EUR 565 million; Net leverage at 2.5xUnderlying EPS EUR 1.33 (up +3.4% to EUR 1.02 excluding fair value change in equity derivatives);Reported EPS of EUR 0.8638% of 2025 EUR 250 million share buyback completedA message from Rafa Oliveira, CEO of JDE Peet’s “We are very pleased with our business and financial results in the first half of 2025. Our performance was broad-based and strong across top-line, profitability and cash flow, despite operating in a challenging...

H1 2025: Outstanding delivery of Nexans’ model, 2025 guidance upgraded

Written by Customer Service on July 30, 2025. Posted in Earnings Releases And Operating Results.

H1 2025: Outstanding delivery of Nexans’ model+4.9% organic growth driven by the performance of our Electrification businesses (+7.8% organic growth)Record EBITDA and ongoing margin improvementsLynxeo disposal successfully completed 2025 guidance upgradedStrong half-year results reflecting the strengths of Nexans’ business model and quality of executionH1 2025 standard sales of €3.8 billion (current sales of €4.7 billion), up +4.9% organically and Q2 2025 standard sales of €2.0 billion, up +5.7% organically Strong Electrification businesses, up +7.8% organically in H1 2025 Record adjusted EBITDA of €441 million, up +7.0% year-on-year, adjusted EBITDA margin at 11.7% of standard sales, up +10 bps Electrification adjusted EBITDA significantly up +17.2% year-on-year, adjusted EBITDA margin at 13.7% of standard sales with structural improvements...

Hepsor AS consolidated unaudited interim report for Q2 2025 and six months

Written by Customer Service on July 30, 2025. Posted in Public Companies.

Hepsor’s consolidated revenue for Q2 2025 amounted to 13.9 million euros (Q2 2024: 5.2 million euros), and revenue for the first half of the reporting year was 22.1 million euros (H1 2024: 7.4 million euros). The Group’s net profit amounted to 0.4 million euros for the second quarter (Q2 2024: net loss of 0.6 million euros), including a net profit attributable to the owners of the parent company of 0.02 million euros (Q2 2024: net loss of 0.6 million euros). The Group’s net profit for the first half of the year was 0.3 million euros (H1 2024: net loss of 1.5 million euros), of which a net loss of 0.2 million euros was attributable to the owners of the parent company (H1 2024: 1.5 million euros). The net loss of the parent company was affected by an income tax expense of 0.3 million euros arising from the distribution of dividends...

Larimar Therapeutics Announces Pricing of Underwritten Public Offering

Written by Customer Service on July 30, 2025. Posted in Public Companies.

BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the pricing of its previously announced underwritten public offering of 18,750,000 shares of its common stock at a price to the public of $3.20 per share. The aggregate gross proceeds to Larimar from this offering are expected to be $60.0 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Larimar has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 shares of its common stock at the public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by Larimar. The offering is expected...

Nokia powers Surge’s subsea network, boosting affordable broadband for millions in Indonesia

Written by Customer Service on July 30, 2025. Posted in Public Companies.

Press ReleaseNokia powers Surge’s subsea network, boosting affordable broadband for millions in IndonesiaSurge’s new subsea network will enhance regional data center interconnectivity while expanding affordable broadband access to over 40 million people across Indonesia. Leveraging Nokia’s 1830 Photonic Service Switch (PSS) platform, Surge can now deliver high-speed optical transmission between Indonesia and Singapore.30 July 2025Jakarta, Indonesia and Espoo, Finland – Nokia today announced that PT Solusi Sinergi Digital Tbk (Surge), a leading digital infrastructure provider in Indonesia, has deployed Nokia’s subsea optical solution to connect Jakarta and Singapore. This new subsea network will boost regional data center interconnectivity and support Surge’s mission to expand affordable broadband access to underserved communities...

Quarterly Activities Report

Written by Customer Service on July 30, 2025. Posted in Earnings Releases And Operating Results.

for the three months ended 30 June 2025(figures are unaudited and in A$ except where stated) TORONTO, July 29, 2025 (GLOBE NEWSWIRE) — June 2025 QuarterDuring the Quarter ending 30 June 2025 (June Quarter), Xanadu Mines Ltd (Xanadu or the Company) focused on strategic funding options to progress the Kharmagtai Copper and Gold Project (Kharmagtai). This resulted in an off-market takeover bid from Bastion Mining Pty Ltd (Bastion), which the Board recommended to shareholders. At the time of this report, Bastion has acquired a relevant interest exceeding 90% of Xanadu shares and issued a Notice of Compulsory Acquisition for all remaining shares outstanding1. Key Highlights:Xanadu entered into an exclusivity period with Zijin Mining Group Co. Ltd. (Zijin) on 7 April 2025 to discuss a range of potential corporate transactions. The...

Day: July 30, 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals